Beyond Air Earnings Call Transcripts
Fiscal Year 2026
-
Nitric oxide delivery technology is expanding globally, with FDA and CE mark approvals and a second-generation system expected to drive further growth. Quarterly revenue rose 105% year-over-year, and international expansion is underway, with new clinical data in cancer to be presented soon.
-
Revenue doubled year-over-year to $2.2M, with strong hospital adoption and improved gross margin. Operating expenses and net loss declined significantly, and recent financings extend cash runway into 2027. Gen 2 LungFit PH approval is expected by end of 2026.
-
A novel nitric oxide delivery system offers safer, greener, and more cost-effective treatment, with a second-generation device set to drive U.S. and global market expansion. Robust R&D in infectious disease, cancer, and neurology, plus strong patent protection, support long-term growth.
-
Revenue surged 128% year-over-year to $1.8M in Q2 FY2026, with robust international expansion and a new capital purchase model introduced. Operating expenses and net loss declined significantly, and guidance was updated to $8–$10M for FY2026.
-
Q1 FY2026 revenue grew 157% year-over-year to $1.8M, driven by strong LungFit PH adoption and new contracts. Operating expenses and cash burn were significantly reduced, and FY2026 revenue guidance of $12M–$16M was reaffirmed, with international expansion accelerating.
Fiscal Year 2025
-
Revenue surged 220% to $3.7M in FY2025, driven by U.S. hospital adoption and international expansion. FY2026 guidance is $12–$16M, with further cost reductions and new product launches expected to boost growth. Net loss narrowed and cash burn fell 28%.
-
Sequential revenue growth driven by new hospital contracts and global expansion, with CE Mark approval enabling EU entry. Net loss narrowed year-over-year, cash burn reduced, and cost controls extended runway through spring 2026.
-
A novel nitric oxide delivery system is gaining traction with FDA and CE approvals, strong safety data, and expanding global partnerships. The company expects to meet revenue targets, launch a next-gen device for transport, and advance its pipeline in respiratory and oncology indications.
-
Revenue quadrupled year-over-year to $0.8M, driven by a 60% increase in hospital clients and new partnerships. Gross margins are expected to turn positive by March 2025, with cost reductions and recent financings extending the cash runway to 18 months.
Fiscal Year 2024
-
Debt restructuring and CE Mark approval have strengthened financials and enabled global expansion. Leadership changes and product upgrades have accelerated adoption, while the next-generation system is expected to drive significant growth starting in fiscal 2027.
-
Fiscal 2024 saw revenue growth, strong customer retention, and expanded device use, but gross margin and net loss were impacted by upgrade costs and R&D. FY2025 guidance was lowered due to regulatory delays, with growth expected to accelerate in the second half.